Serum levels of second-generation antipsychotics are associated with cognitive function in psychotic disorders

References

• Aalto S, Bruck A, Laine M, Nagren K, Rinne JO. 2005. Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J Neurosci. 25:2471–2477.
   Google Scholar
• American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders. Washington (DC): American Psychiatric Association.
   Google Scholar
• Arts B, Jabben N, Krabbendam L, van Os J. 2011. A 2-year naturalistic study on cognitive functioning in bipolar disorder. Acta Psychiatr Scand. 123:190–205.
   Google Scholar
• Biederman J, Faraone SV. 2005. Attention-deficit hyperactivity disorder. Lancet. 366:237–248.
   Google Scholar
• Carbon M, Correll CU. 2014. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 19:35–53.
   Google Scholar
• Carroll D, Ginty AT, Painter RC, Roseboom TJ, Phillips AC, de Rooij SR. 2012. Systolic blood pressure reactions to acute stress are associated with future hypertension status in the Dutch Famine Birth Cohort Study. Int J Psychophysiol. 85:270–273.
   Google Scholar
• Castberg I, Skogvoll E, Spigset O. 2007. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry. 68:1540–1545.
   Google Scholar
• Castberg I, Spigset O. 2007. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service. Pharmacopsychiatry. 40:107–110.
   Google Scholar
• Castberg I, Westin AA, Spigset O. 2009. Does level of care, sex, age, or choice of drug influence adherence to treatment with antipsychotics? J Clin Psychopharmacol. 29:415–420.
   Google Scholar
• Cohen J. 1992. A power primer. Psychol Bull. 112:155–159.
   Google Scholar
• Cools R, D'Esposito M. 2011. Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry. 69:e113–e125.
   Google Scholar
• Cools R, Gibbs SE, Miyakawa A, Jagust W, D'Esposito M. 2008. Working memory capacity predicts dopamine synthesis capacity in the human striatum. J Neurosci. 28:1208–1212.
   Google Scholar
• Cousins DA, Butts K, Young AH. 2009. The role of dopamine in bipolar disorder. Bipolar Disord. 11:787–806.
   Google Scholar
• Delis DC, Kaplan E, Kramer JH. 2005. The Delis-Kaplan executive function system: D-KEFS. Stockholm, Sweden: Pearson Assessment.
   Google Scholar
• Delis DC, Kramer JH, Kaplan E, Ober BA. 2004. California verbal learning test: CVLT-II. Stockholm, Sweden: Pearson Assessment.
   Google Scholar
• Depp CA, Bowie CR, Mausbach BT, Wolyniec P, Thornquist MH, Luke JR, McGrath JA, Pulver AE, Patterson TL, Harvey PD. 2015. Current smoking is associated with worse cognitive and adaptive functioning in serious mental illness. Acta Psychiatr Scand. 131:333–341.
   Google Scholar
• Elie D, Poirier M, Chianetta J, Durand M, Gregoire C, Grignon S. 2010. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol (Oxford). 24:1037–1044.
   Google Scholar
• First MB, Spitzer RL, Gibbon M, Williams JBW. 1995. Structured clinical interview for DSM-IV axis I disorders: patient edition (SCID-P), version 2. New York: Biometrics Research, New York State Psychiatric Institute.
   Google Scholar
• Firth J, Cotter J, Elliott R, French P, Yung AR. 2015. A systematic review and meta-analysis of exercise interventions in schizophrenia patients. Psychol Med. 45:1343–1361.
   Google Scholar
• Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG. 2007. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch Gen Psychiatry. 64:1115–1122.
   Google Scholar
• Ho BC, Andreasen NC, Dawson JD, Wassink TH. 2007. Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia. Am J Psychiatry. 164:1890–1899.
   Google Scholar
• Hori H, Noguchi H, Hashimoto R, Nakabayashi T, Omori M, Takahashi S, Tsukue R, Anami K, Hirabayashi N, Harada S, et al. 2006. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res. 86:138–146.
   Google Scholar
• Hori H, Yoshimura R, Katsuki A, Hayashi K, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J. 2012. The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients. J Psychiatr Res. 46:757–761.
   Google Scholar
• Huang M, Panos JJ, Kwon S, Oyamada Y, Rajagopal L, Meltzer HY. 2014. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism. J Neurochem. 128:938–949.
   Google Scholar
• Jabben N, Arts B, van Os J, Krabbendam L. 2010. Neurocognitive functioning as intermediary phenotype and predictor of psychosocial functioning across the psychosis continuum: studies in schizophrenia and bipolar disorder. J Clin Psychiatry. 71:764–774.
   Google Scholar
• Kawai N, Yamakawa Y, Baba A, Nemoto K, Tachikawa H, Hori T, Asada T, Iidaka T. 2006. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. Prog Neuropsychopharmacol Biol Psychiatry. 30:1009–1014.
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13:261–276.
   Google Scholar
• Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Rock SL, Woolson S, Tohen M, Tollefson GD, et al. 2006. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry. 59:97–105.
   Google Scholar
• Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Dickinson D, Nelson M, Gold JM, Ball MP, Feldman S, Liu F, Conley RR. 2009. A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry. 70:518–525.
   Google Scholar
• Kim E, Howes OD, Turkheimer FE, Kim BH, Jeong JM, Kim JW, Lee JS, Jang I-J, Shin SG, Kapur S, et al. 2013. The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory: A dual [(11)C]raclopride and [(18) F]FDG imaging study with aripiprazole. Psychopharmacology (Berl). 227:221–229.
   Google Scholar
• Kinghorn WA, McEvoy JP. 2005. Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev Neurother. 5:297–307.
   Google Scholar
• Knowles EE, David AS, Reichenberg A. 2010. Processing speed deficits in schizophrenia: reexamining the evidenceexamining. Am J Psychiatry. 167:828–835.
   Google Scholar
• Ko JH, Ptito A, Monchi O, Cho SS, Van ET, Pellecchia G, Ballanger B, Rusjan P, Houle S, Strafella AP. 2009. Increased dopamine release in the right anterior cingulate cortex during the performance of a sorting task: a [11C]FLB 457 PET study. Neuroimage. 46:516–521.
   Google Scholar
• Kontis D, Theochari E, Kleisas S, Kalogerakou S, Andreopoulou A, Psaras R, Makris Y, Karouzos C, Tsaltas E. 2010. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 34:1333–1341.
   Google Scholar
• Lackner N, Bengesser SA, Birner A, Painold A, Fellendorf FT, Platzer M, Reininghaus B, Weiss EM, Mangge H, McIntyre RS, et al. 2016. Abdominal obesity is associated with impaired cognitive function in euthymic bipolar individuals. World J Biol Psychiatry. 17:535-546.
   Google Scholar
• Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. 2002. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 63:892–909.
   Google Scholar
• Lin CY, Tsai GE, Lane HY. 2014. Assessing and treating cognitive impairment in schizophrenia: current and future. Curr Pharm Des. 20:5127–5138.
   Google Scholar
• Linssen AM, Sambeth A, Vuurman EF, Riedel WJ. 2014. Cognitive effects of methylphenidate in healthy volunteers: a review of single dose studies. Int J Neuropsychopharmacol. 17:961–977.
   Google Scholar
• Meltzer HY, Sumiyoshi T. 2008. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?. Behav Brain Res. 195:98–102.
   Google Scholar
• Monchi O, Ko JH, Strafella AP. 2006. Striatal dopamine release during performance of executive functions: A [(11)C] raclopride PET study. Neuroimage. 33:907–912.
   Google Scholar
• Morrens M, Wezenberg E, Verkes RJ, Hulstijn W, Ruigt GS, Sabbe BG, 2007. Psychomotor and memory effects of haloperidol, olanzapine, and paroxetine in healthy subjects after short-term administration. J Clin Psychopharmacol. 27:15–21.
   Google Scholar
• Nasrallah HA, 2008. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 13:27–35.
   Google Scholar
• Nielsen RE, Levander S, Kjaersdam TG, Jensen SO, Ostergaard CT, Leucht S, 2015. Second-generation antipsychotic effect on cognition in patients with schizophrenia-a meta-analysis of randomised clinical trials. Acta Psychiatr Scand. 131:185–196.
   Google Scholar
• Pedersen G, Hagtvet KA, Karterud S, 2007. Generalizability studies of the Global Assessment of Functioning-Split version. Compr Psychiatry. 48:88–94.
   Google Scholar
• Radhakrishnan R, Wilkinson ST, D'Souza DC, 2014. Gone to Pot - A Review of the Association between Cannabis and Psychosis. Front Psychiatry. 5:54.
   Google Scholar
• Riedel M, Spellmann I, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, Opgen-Rhein M, Matz J, Seemüller F, Obermeier M, et al. 2010. Effect of aripiprazole on cognition in the treatment of patients with schizophrenia. Pharmacopsychiatry. 43:50–57.
   Google Scholar
• Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, Uchida H. 2013. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull. 39:564–574.
   Google Scholar
• Salavati B, Rajji TK, Price R, Sun Y, Graff-Guerrero A, Daskalakis ZJ, 2015. Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation. Schizophr Bull. 41:44–56.
   Google Scholar
• Simonsen C, Sundet K, Vaskinn A, Birkenaes AB, Engh JA, Faerden A, Jónsdóttir H, Ringen PA, Opjordsmoen S, Melle I, et al. 2011. Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group. Schizophr Bull. 37:73–83.
   Google Scholar
• Soderberg MM, Dahl ML, 2013. Pharmacogenetics of olanzapine metabolism. Pharmacogenomics. 14:1319–1336.
   Google Scholar
• Spitzer RL, Williams JB, Kroenke K, Linzer M, deGruy FV, Hahn SR, Brody D, Johnson JG. 1994. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA. 272:1749–1756.
   Google Scholar
• Steen NE, Methlie P, Lorentzen S, Hope S, Barrett EA, Larsson S, Mork E, Almås B, Løvås K, Agartz I, et al. 2011. Increased systemic cortisol metabolism in patients with schizophrenia and bipolar disorder: a mechanism for increased stress vulnerability? J Clin Psychiatry. 72:1515–1521.
   Google Scholar
• Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY, 2007. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 95:158–168.
   Google Scholar
• Suridjan I, Rusjan P, Addington J, Wilson AA, Houle S, Mizrahi R, 2013. Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task. J Psychiatry Neurosci. 38:98–106.
   Google Scholar
• Takahashi H, 2013. PET neuroimaging of extrastriatal dopamine receptors and prefrontal cortex functions. J Physiol Paris. 107:503–509.
   Google Scholar
• Uchida H, Rajji TK, Mulsant BH, Kapur S, Pollock BG, Graff-Guerrero A, Menon M, Mamo DC. 2009. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. J Clin Psychopharmacol. 29:571–575.
   Google Scholar
• van Os J, Kapur S, 2009. Schizophrenia. Lancet. 374:635–645.
   Google Scholar
• Wechsler D, Wycherley RJ, Benjamin L. 2008. Wechsler Memory Scale: WMS-III. Stockholm, Sweden: Pearson Assessment.
   Google Scholar
• Wechsler D. 2003. Wechsler Adult Intelligence Scale: WAIS-III. Stockholm, Sweden: Pearson Assessment.
   Google Scholar
• Wechsler D. 2007. Wechsler Abbreviated Scale of Intelligence (WASI). Norwegian manual supplement. Stockholm, Sweden: Pearson Assessment.
   Google Scholar
• Woodward ND, Purdon SE, Meltzer HY, Zald DH, 2005. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 8:457–472.
   Google Scholar
• Yasui-Furukori N, Kaneda A, Sugawara N, Tomita T, Kaneko S, 2012. Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. J Psychopharmacol (Oxford). 26:806–812.
   Google Scholar